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Letters to the
Editor
Malignant margin in wedge
resection for peripheral lung cancer
and adjuvant radiotherapy
To the Editor:
We read with interest the article by Shen-
nib and associates1 regarding wedge resec-
tion and local radiotherapy for peripheral
lung cancer in high-risk patients. They
stated that pathologically staged T1 lesions
can be successfully resected in 75% of
cases; however, narrow resection margins
remain a concern. Knowing the efficacy of
local radiotherapy, the type of failure,
whether there is local-regional recurrence,
and the malignant status of surgical mar-
gins is crucial.
To obtain an accurate diagnosis of ma-
lignant status at the surgical margins is
sometimes difficult because stapled resec-
tion is most frequently used. Staples have
to be removed to examine the margins
pathologically. Therefore pathologic diag-
nosis with frozen sections is not an option,
although a method of cytology can be used
to diagnose the malignant status of surgical
margins. We found that a cytologic method
to diagnose the malignant status of surgical
margins can predict the risk of recurrences
at the surgical margins.2 In addition, we
found that an optimal distance from the
tumor to the surgical margin was more than
the maximum tumor diameter to obtain a
safe margin. In the resent issue the authors
defined a sufficient margin distance to be
more than 1 cm. When a tiny peripheral
lesion less than 1 cm in diameter is re-
moved, margin distance of less than 1 cm
could be sufficient. Margin distance and
margin cytology could be criteria of adju-
vant radiotherapy.
It is generally accepted that limited lung
resection is safe and effective in a selected
group of patients. However, there is a great
concern about local-regional recurrences.
The percentage of local-regional recur-
rences is reported to be 39% in a study
containing more than 100 cases conducted
by Landreneau and coworkers.3 Radiation
therapy has been indicated, either brachy-
therapy4,5 or local radiotherapy,1 to prevent
such failures. As such, type of failure is a
matter of concern. As shown in Table 1,
Lee and colleagues4 and Fernando and as-
sociates5 reported that the local-regional
recurrence ratio was reduced to 2% to 6%
in a group of patients who underwent
wedge resection and brachytherapy. Unfor-
tunately, the frequency of recurrences is
not stated in the recent report.1 In addition,
an adverse effect of pneumonitis was ob-
served in 14% in cases of local radiother-
apy. Considering this, brachytherapy might
be a more acceptable method than local
radiotherapy if the local-regional recur-
rence ratio was more than or equal to that
of brachytherapy.
Adjuvant radiotherapy in cases of lim-
ited resection of lung cancer might be a
hopeful treatment in selected patients. Ac-
curate diagnosis of the malignant status of
surgical margins and efficacy to prevent
surgical margin recurrence are matters
TABLE 1. Local recurrence after wedge resection and regional radiotherapy for
peripheral lung cancer
Authors Year N Selection
Complication
pneumonitis
(%)
Local-
regional
recurrence
(%)
Lee et al4* 2003 31 Compromise 0 6
Fernando et al5* 2004 154 Compromise 0 2
Shennib et al† 2004 27 Compromise 14 NA
NA, Not applicable. *Brachytherapy with iodine 125. †Local radiotherapy.
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of concern. We hope to see the mature
follow-up results of CALGB 9335.
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Reply to the Editor:
Dr Sawabata and colleagues address some
interesting and yet undefined issues related
to resection of small lung cancer lesions.
Just what is the safe limit of a resection
margin for a lung cancer, and how does the
technique of wedge resection affect the ex-
tent of this margin and the ability to do
facile, prompt, and accurate pathologic as-
sessment? None of the answers to these
questions are yet known, and only carefully
conducted studies of cohorts of resected
patients with T1 size lesions will be able to
answer them. We certainly will be looking
at long-term follow-up on our CALGB
9335 patients to attempt to answer this.
In this study the readers are reminded
that study subjects were at high cardiopul-
monary risk and were compromised and
that both survival and locoregional recur-
rence of this high-risk population might not
reflect on similar patients with T1 lesions
with near-normal cardiopulmonary status
undergoing resection. It is possible, for ex-
ample, to assume that healthier patients might
encourage surgeons to perform wider resec-
tion margins, whereas sicker patients with
bad lungs will lead surgeons to more con-
servative narrower resections.
Staple lines at resection margins cer-
tainly pose a challenge to pathologists
when performing frozen sections, but over-
all, this is certainly less of a hassle for the
surgeon who will have to deal with air
leaks if staple resection is not performed.
Furthermore, we do not know how tumor
size will affect outcome and whether resec-
tion margins for subcentimeter lesions will
necessarily lend themselves to potentially
narrower resection than larger tumors. Per-
haps the biology of the lung cancer, rather
than its size, will have more effect on the
safety of resection margins.
Finally, newer technologies are making
their way into our practice and not just
brachytherapy, which potentially offers
less lung injury, and more concentrated
therapy. Image-gated radiotherapy and ra-
diofrequency ablation might also be enter-
tained as potential alternative approaches
either alone or as adjuncts to limited sur-
gical resection if studies validate their ef-
ficacy.
Hani Shennib, MD
Department of Oncology
McGill University
2215 Dover Rd
Montreal, Quebec H3P 2N6, Canada
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Whatever the approach, cutting strut
chordae would not smell as sweet
To the Editor:
With the first clinical application of Messas
and colleagues’ ovine trial,1 Fayad and col-
leagues2 reported the case of a patient with
chronic ischemic mitral regurgitation (CIMR)
who was managed successfully with strut chor-
dae severing through an exclusive aortotomy
and concomitant coronary artery bypass graft-
ing. Although encouraging midterm results
were reported, the objection can be raised
to the authors’ rationale of a “cut-and-go”
approach in the face of such a complex
pathophysiologic entity. As indicated by
the authors, the factors involved in the gen-
esis of CIMR are multiple and intricate,
reflecting the complexity in preoperative
analysis of CIMR mechanisms attempted at
surgical planning. Similarly, it is our belief
that factors involved in the postoperative
regression of moderate CIMR are too com-
plex to be ascribed to a given procedure,
especially when taking into account reverse
ventricular remodeling after coronary ar-
tery bypass grafting and possible improve-
ment in intramyocardial conduction, 2 fac-
tors that are not taken into account in
experimental models of CIMR.
The direct access offered by exclusive
aortotomy to approach strut chordae is ap-
pealing, but that is at the loss of perioper-
ative analysis of mitral apparatus, still of
paramount importance in surgical decision-
making. In our experience, the superior left
atrial approach offers an adequate surgical
field, even in the setting of CIMR or rheu-
matic disease, and for preprocedural and
postprocedural functional analyses of mi-
tral apparatus. Other advantages of a supe-
rior left atrial approach include a lesser
distortion of mitral annulus and likelihood
of perioperative or postoperative bleeding
compared with an interatrial approach or
aortotomy, respectively.
The authors’ technique is conceived ac-
cording to the conclusions of an experi-
Figure 1. Secondary chordae seen through
aortotomy. The functional division line of
anterior leaflet according to papillary mus-
cle complexes (PMCs) (dotted arrow). Each
half is supported by a strut chorda. Strut
chordae belonging to APM and PPM. APM,
Anterior papillary muscle; PPM, posterior
papillary muscle.
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